ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Exploring Therapeutic Targets From Spreading Patterns Against Respiratory Syncytial Virus.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Generation of human-induced pluripotent stem cell-derived lung organoids for modeling respiratory syncytial virus infection and pulmonary injury.Frontiers in immunology · 2026Article
- Epidemiological and clinical characteristics of respiratory syncytial virus infection in hospitalized neonates in Suzhou.Translational pediatrics · 2025Article
- Exploring Therapeutic Targets From Spreading Patterns Against Respiratory Syncytial Virus.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human respiratory syncytial virus (RSV) is a pathogen that causes severe respiratory illness in humans, primarily infecting infants, young children, the elderly, and adults with chronic health conditions. Each year, approximately 3.6 million children under the age of 5 are hospitalized worldwide, with over 100 000 fatalities reported. Currently, available RSV vaccines and antiviral drugs have several limitations, including inadequate immune persistence, limited applicability to specific populations, strict timing of treatment, and the risk of adverse reactions. RSV spreads through three main infection modes: syncytia formation, receptor-dependent infection of free viral particles, and transmission via actin filaments. These modes of transmission are key pathways that contribute to viral spread and pathogenicity while exposing potential targets for prevention and treatment. This is a complex process involving multiple aspects that remain not fully understood. Here, we review the mechanisms by which RSV infects and spreads within the host and explore the role of host factors in these processes, aiming to provide a theoretical and practical basis for identifying potential antiviral targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.